Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrane, Karim, Campedel, Luca, Le Meur, Coline, Abgral, Ronan, Kharroubi, Dris, Cadranel, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514716/
https://www.ncbi.nlm.nih.gov/pubmed/34660618
http://dx.doi.org/10.3389/fmed.2021.691253
_version_ 1784583454049959936
author Amrane, Karim
Campedel, Luca
Le Meur, Coline
Abgral, Ronan
Kharroubi, Dris
Cadranel, Jacques
author_facet Amrane, Karim
Campedel, Luca
Le Meur, Coline
Abgral, Ronan
Kharroubi, Dris
Cadranel, Jacques
author_sort Amrane, Karim
collection PubMed
description Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[(18)F] fluoro-D-glucose positron emission tomography-computed tomography ((18)F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the (18)F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC.
format Online
Article
Text
id pubmed-8514716
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85147162021-10-15 Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer Amrane, Karim Campedel, Luca Le Meur, Coline Abgral, Ronan Kharroubi, Dris Cadranel, Jacques Front Med (Lausanne) Medicine Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[(18)F] fluoro-D-glucose positron emission tomography-computed tomography ((18)F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the (18)F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC. Frontiers Media S.A. 2021-09-30 /pmc/articles/PMC8514716/ /pubmed/34660618 http://dx.doi.org/10.3389/fmed.2021.691253 Text en Copyright © 2021 Amrane, Campedel, Le Meur, Abgral, Kharroubi and Cadranel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Amrane, Karim
Campedel, Luca
Le Meur, Coline
Abgral, Ronan
Kharroubi, Dris
Cadranel, Jacques
Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
title Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
title_full Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
title_fullStr Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
title_full_unstemmed Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
title_short Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
title_sort case report: two rare cases of complete metabolic response to crizotinib in patients with rearranged ros1 and alk metastatic non-small lung cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514716/
https://www.ncbi.nlm.nih.gov/pubmed/34660618
http://dx.doi.org/10.3389/fmed.2021.691253
work_keys_str_mv AT amranekarim casereporttworarecasesofcompletemetabolicresponsetocrizotinibinpatientswithrearrangedros1andalkmetastaticnonsmalllungcancer
AT campedelluca casereporttworarecasesofcompletemetabolicresponsetocrizotinibinpatientswithrearrangedros1andalkmetastaticnonsmalllungcancer
AT lemeurcoline casereporttworarecasesofcompletemetabolicresponsetocrizotinibinpatientswithrearrangedros1andalkmetastaticnonsmalllungcancer
AT abgralronan casereporttworarecasesofcompletemetabolicresponsetocrizotinibinpatientswithrearrangedros1andalkmetastaticnonsmalllungcancer
AT kharroubidris casereporttworarecasesofcompletemetabolicresponsetocrizotinibinpatientswithrearrangedros1andalkmetastaticnonsmalllungcancer
AT cadraneljacques casereporttworarecasesofcompletemetabolicresponsetocrizotinibinpatientswithrearrangedros1andalkmetastaticnonsmalllungcancer

Ejemplares similares